ACTIVITY INFORMATION
Release Date: January 1, 2008
Expiration Date: December 31, 2009
Activity Code: 09HC08-DE01
Sponsor
Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ), UMDNJ-Center for Continuing & Outreach Education.
Grantor Acknowledgement
This activity is supported by an educational grant from NJDHSS Division of HIV/AIDS Services through a MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”
Target Audience
This activity is designed for physicians and nurses, and for other health care professionals in New Jersey who are involved in the care of persons with HIV/AIDS.
Statement of Need
In NJ and other areas of high HIV/AIDS prevalence, many HIV-positive patients have taken multiple treatment regimens, and their virus has become resistant to multiple classes of HIV medications. Drug interactions and toxicity also led to the need to change from first-line and salvage therapies for HIV patients who have become “treatment-experienced” or resistant to more than one medication or class of medications.
In 2007, two new agents in two new antiretroviral classes were approved by the FDA for use with treatment-experienced HIV patients. Maraviroc is an entry inhibitor, which was FDA approved on August 6, 2007 for treatment-experienced HIV adults infected with only CCR5-tropic HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir, an Integrase inhibitor, was FDA approved on October 12, 2007 for the treatment of HIV-1 infection in treatment-experienced adult patients who have HIV-1 strains that are resistant to multiple antiretroviral agents.
New antiretroviral agents can only be prescribed once there is laboratory confirmation, through genotypic tests, that the patient’s HIV strain will respond to these specific treatments.
Learning Objectives
Upon completion of this learning activity, the reader should be able to:
- Outline the signs and test results that would document that a patient has
developed toxicity and/or resistance to their current therapy.
- Discuss the role of integrase inhibitors in treatment experienced HIV-positive
patients.
- Identify the role of entry inhibitors in treatment experienced HIV-positive patients.
- Explain viral tropism and the role of tropism testing in the management of HIV
patients.
Method of Instruction
Participants should read the learning objectives and review the activity in its entirety, review the material, and complete the self-assessment test, a series of multiple-choice and True/ False questions.
Upon completing this activity as designed and achieving a passing score of 70% or more on the self-assessment test, participants will receive a credit letter and the test answer key four (4) weeks after receipt of the self-assessment test, registration, and evaluation form. Estimated time to complete this activity as designed is 1.25 hours.
Accreditation
Physicians:
UMDNJ–Center for Continuing and Outreach Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. UMDNJ–Center for Continuing and Outreach Education designates this educational activity for a maximum of 1.25 hours of AMA PRA category 1 credit™. Each physician should claim only those credits that he/she actually spent in the activity.
Nurses:
UMDNJ-Center for Continuing & Outreach Education is an approved provider of continuing nursing education by the New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is awarded 1.25 contact hours. (60 minute CH.)
Provider approved by the California Board of Registered Nursing, Provider Number CEP 13780.
Review
The activity was prepared in accordance with the ACCME Essentials. This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Patricia C. Kloser, MD, MPH, FACP. This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Bonnie Abedini, RN, MSN; Mary C. Krug, RN, MSN, APN-C; and Debbie Y. Mohammed, MS, MPH, APRN-BC, AACRN.
Faculty
Amrita Kaur, DO, is Infectious Disease Fellow, Garden State Infectious Disease Associates and completed a Public Health Rotation with the NJ Dept. of Health and Senior Services,Division of HIV/AIDS Services.
Sindy M. Paul, MD, MPH, FACPM, is the Medical Director of the NJ Dept. of Health and Senior Services, Division of HIV/AIDS Services; Assistant Clinical Professor at the University of Medicine & Dentistry of New Jersey (UMDNJ); and past President, New Jersey Board of Medical Examiners.
Faculty Disclosure Declarations
The following have no financial relationships to disclose: authors: Amrita Kaur, DO; Sindy M. Paul, MD, MPH, FACPM; Patricia C. Kloser,MD, MPH, FACP; editor: Kimi Nakata, MSW, MPH and field testers: Bonnie Abedini, BSN, MS; Mary C.Krug, RN, MSN, APN-C, and Debbie Y.Mohammed, MS, MPH, APRN-BC, AACRN.
Off-Label Usage Disclosure
This activity does not contain information
of commercial products/devices that are
unlabeled for use or investigational uses
of products not yet approved.
Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDHSS-Division of HIV/AIDS Services, UMDNJ, or any manufacturer of pharmaceuticals. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.
Copyright© 2008 UMDNJ-Center for Continuing & Outreach Education. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ-Center for Continuing & Outreach Education.
Editor’s note:
Following the American Medical Association guideline, UMDNJ-CCOE will list trade names with capital letters but will no longer note ® and T status of medications, as the US Federal Dilution Trademark Act does not require these designations in publications. |
